Research Papers

25 of 522 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Linezolid brain penetration in neurointensive care patients.
Hosmann A; Moser MM; van Os W; Gramms L; Al Jalali V; Sanz Codina M; Plöchl W; Lier C; Kees F; Dorn C; Rössler K; Reinprecht A; Zeitlinger M.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
Early-career general practitioners' antibiotic prescribing for acute infections: a systematic review.
Baillie EJ; Merlo G; Van Driel ML; Magin PJ; Hall L.
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Registered Funding Declared
Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacter…
Montelin H; Camporeale A; Hallgren A; Angelin M; Hogvall J; Östholm Balkhed Å; Vading M; Giske CG; Tängdén T; Swedish ESBL study group .
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time-kill e…
Olsson A; Malmberg C; Zhao C; Friberg LE; Nielsen EI; Lagerbäck P; Tängdén T.
J Antimicrob Chemother (Unknown)
Published: 2024
4/6 Transparent
Data Funding Declared
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the …
Abdullahi A; Diaz AG; Fopoussi OM; Beloukas A; Defo VF; Kouanfack C; Torimiro J; Geretti AM.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
Streptococcus suis serotype 9 in Italy: genomic insights into high-risk clones with emerging resistance to penicillin.
Massacci FR; Cucco L; Panicciá M; Luppi A; Albini E; Peruzzo A; Ferroni L; Ustulin M; Orsini M; Magistrali CF.
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Data Funding Declared
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
Omar S; Whitfield MG; Nolan MB; Ngom JT; Ismail N; Warren RM; Klopper M.
J Antimicrob Chemother (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
A pharmacy-led sore throat test and treat (STTT) service: antigen testing and antibiotic supply rates during the period…
Mantzourani E; Ahmed H; Evans A; Gunnarsson R; Cannings-John R.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with …
Combrinck J; Tshavhungwe P; Rohlwink U; Enslin N; Thango N; Lazarus J; Kriegler K; Castel S; Abdelgawad N; Mcilleron H; Denti P; Wiesner L; Figaji A.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
Clostridium neonatale antimicrobial susceptibility, genetic resistance determinants, and genotyping: a multicentre spat…
Ferraris L; Delannoy J; Mazuet C; Diancourt L; Mesa-Schein V; Barbut F; Aires J.
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Data Funding Declared
Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in primary care: a study bas…
Hosaka Y; Muraki Y; Kajihara T; Kawakami S; Hirabayashi A; Shimojima M; Ohge H; Sugai M; Yahara K.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
Emergence of multiple fluconazole-resistant Candida parapsilosis sensu stricto clones with persistence and transmission…
Ning YT; Sun TS; Dai RC; Luo ZY; Yu SY; Zhang G; Mei YN; Lin YL; Hasi CL; Chen SCA; Kong FR; Xiao M; Xu YC; Zhang L.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
UK clinicians' attitudes towards the application of molecular diagnostics to guide antibiotic use in ICU patients with …
Stewart SF; Pandolfo AM; Moon Z; Jani Y; Brett SJ; Brealey D; Singh S; Enne VI; Livermore DM; Gant V; Horne R.
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbap…
Lodise TP; Yucel E; Obi EN; Watanabe AH; Nathanson BH.
J Antimicrob Chemother (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Strategies to reduce antimicrobials in livestock and aquaculture, and their impact under field conditions: a structured…
Sucena Afonso J; El Tholth M; Mcintyre KM; Carmo LP; Coyne L; Manriquez D; Raboisson D; Lhermie G; Rushton J.
J Antimicrob Chemother (Unknown)
Published: 2024
2/6 Transparent
Funding Declared
An overview of COVID-19 global epidemiology and discussion of potential drivers of variable global pandemic impacts.
Ashmore P; Sherwood E.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Lessons identified for a future pandemic.
Cunningham N; Hopkins S.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Foreword.
Hopkins S.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015-16 to 2020-21 seasons: …
Tsuzuki S; Murata F; Maeda M; Asai Y; Koizumi R; Ohmagari N; Fukuda H.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Swedish multicentre study of target attainments with β-lactams in the ICU: which MIC parameter should be used?
Smekal AK; Furebring M; Lipcsey M; Giske CG.
J Antimicrob Chemother (Unknown)
Published: 2023
2/6 Transparent
Funding Declared
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resista…
Lee SY; Gill CM; Nicolau DP; ERACE-PA Global Study Group.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Exploring synergy between azole antifungal drugs and statins for Candida auris.
Halliday C; Kim HY; Tay E; Chen SCA; Alffenaar JW.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.
Veerman K; Goosen J; Spijkers K; Jager N; Heesterbeek P; Telgt D.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and …
Cornely OA; Ostermann H; Koehler P; Teschner D; Limburg E; Kramer WG; Barbat SH; Tawadrous M; Hodges MR.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A hydrophilic polyimidazolium antibiotic targeting the membranes of Gram-negative bacteria.
Chen Y; Yong M; Li M; Si Z; Koh CH; Lau P; Chang YW; Teo J; Chan-Park MB; Gan YH.
J Antimicrob Chemother (Unknown)
Published: 2023
3/6 Transparent
Funding Declared